AGP Executive Report
Last update: 9 hours agoReproductive Rights in Focus: A new report highlights how Liechtenstein’s abortion rules are among the strictest in Europe, allowing abortions only in cases of rape or life-threatening circumstances—pushing many people to travel to Austria or Switzerland, where access can still be limited and information is hard to find. Cancer Care Updates: The European Commission has authorized Gilead’s Trodelvy (sacituzumab govitecan) with Merck’s Keytruda for certain first-line metastatic triple-negative breast cancer patients with PD-L1 (CPS ≥10), including Liechtenstein. Rare Disease Treatment: Acadia’s DAYBU (trofinetide) has received EU approval as the first and only treatment for neurobehavioral symptoms of Rett syndrome for patients aged five and older, with Liechtenstein included—though pricing and reimbursement talks may delay access. Healthcare Tech & Devices: Liechtenstein-based RefluxStop reports strong European growth and says FDA approval has been secured, setting up a U.S. launch. Policy & Access: Separate coverage notes that Liechtenstein is included in broader European regulatory approvals, underscoring how EU decisions can quickly affect local treatment options.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
